ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lilly Will Acquire Protein Drug Firm

by Rick Mullin
July 12, 2010 | APPEARED IN VOLUME 88, ISSUE 28

Eli Lilly & Co. has agreed to acquire Alnara, a privately held biotechnology company that develops protein therapeutics to treat metabolic diseases. “The acquisition of Alnara provides Lilly with a promising entry into enzyme replacement therapy,” says Bryce Carmine, president of Lilly BioMedicines. Alnara’s lead product, liprotamase, is a pancreatic enzyme replacement therapy that is under FDA review for the treatment of exocrine pancreatic insufficiency, a condition associated with cystic fibrosis and chronic pancreatitis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment